Health
Pancreatic cancer pill daraxonrasib shows tumour shrinkage and longer survival in two trials
Coverage
2 reports · over 17 hours
Early and late-stage trials of the daily drug reported halted tumour growth in newly diagnosed patients and longer median survival in previously treated metastatic disease.
- In a phase 1/2 trial of 61 newly diagnosed patients, tumours stopped growing in 90% and shrank or disappeared in just over 60%, investigators reported.
- About one in 12 patients in that trial had no tumour detectable on CT scans, results presented to the EORTC–NCI–AACR Symposium 2026 showed.
- A separate phase 3 trial of roughly 500 previously treated metastatic patients recorded median survival of 13.2 months, against 6.7 months on chemotherapy.
- Daraxonrasib blocks RAS mutations that drive tumour growth and already holds approval for use in the United States.

